Neurology | Home | MIMS Malaysia

Clopidogrel-aspirin of secondary prevention benefit within 21 days of minor stroke or TIA

Natalia Reoutova, 6 days ago

A pooled analysis of two large-scale randomized clinical trials demonstrated that the significant secondary prevention benefit of dual antiplatelet therapy was confined to the first 21 days of administering clopidogrel-aspirin following minor ischaemic stroke or high-risk transient ischaemic attack (TIA).

Functional brain connectivity predicts antidepressant response in major depression

04 Oct 2019

Specific functional network-based moderators of treatment outcome have been identified, and these involve brain networks affected by major depression, reports a study. In addition, a favourable response for an antidepressant medication appears to be influenced by functional connectivity patterns of brain regions between and within networks.

Elemental metabolism dynamics different for ADHD, ASD and neurotypical controls

Natalia Reoutova, 04 Oct 2019

A study of 74 Swedish twins and triplets discordant for attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) and other neurodevelopmental diagnoses identified a consistent reduction in regularity and complexity of cobalt, lead and vanadium cycles in individuals with ADHD.

Poststroke anxiety linked to greater depressive symptoms, younger age

01 Oct 2019

Generalized anxiety symptoms commonly occur after stroke or transient ischaemic attack and are associated with younger age and greater depressive symptoms, and these relationships persist even among patients without severe comorbid depressive symptoms, as reported in a recent study.

Original New Drug Application Approvals by US FDA (16 - 30 September 2019)

01 Oct 2019

New drug applications approved by US FDA as of 16 - 30 September 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Shifting paradigms in MS management: Early, optimized interventions improve patient outcomes

04 May 2018

Multiple sclerosis (MS) is one of the most common neurological disorders – affecting over 2.3 million people globally – and it is the leading cause of nontraumatic disability in young adults. However,the availability of supportive resources and services for people with MS is scarce in many regions of the world. In Malaysia, the prevalence of MS is estimated at 2-3/100,000; the current Malaysian clinical practice guidelines on the management of MS recommend disease modifying agents, such as interferon-β and teriflunomide, as first-line therapeutic agents. In this article, Dr Singer - in partnership with Sanofi and the Malaysian Society of Neurosciences - shares his insights into managing MS dynamically, highlighting the importance of early intervention in improving patient outcomes.

Management of dementia beyond cognition – a deeper look into BPSD and CVD

13 Dec 2017

At the Schwabe-Menarini lunch symposium of the 11^th International Congress of the Asian Society AgainstDementia (ASAD) 2017 held in Bangkok, Thailand, Professor Ralf Ihl highlighted the role of standardized Gingko biloba extract EGb 761^®for the treatment of patients with behavioural and psychological symptoms of dementia (BPSD). Meanwhile, Associate Professor Nagaendran Kandiah presented clinical findings on the association between cerebrovascular disease (CVD) and dementia, and emphasized the role of EGb 761^®in the management of dementia with CVD.

Hypertension and cholesterol lowering interventions do not reduce cognitive decline

Roshini Claire Anthony, 22 Nov 2016

Blood pressure lowering medications and statins do not prevent cognitive and functional decline in elderly patients, according to results of the HOPE-3 trial* presented at the Scientific Sessions of the American Heart Association (AHA 2016) held recently in New Orleans, Louisiana, US.

An uncommon cause of hyperthyroidism

Dr. Rose Zhao-Wei Ting, 16 Nov 2016

A 55-year-old man presented with almost one year history of heat intolerance, mild palpitation and significant weight loss. Free T3 and T4 were elevated with normal TSH. Patient had suboptimal response to carbimazole therapy.

Active lifestyle may delay Alzheimer’s disease progression

Roshini Claire Anthony, 13 Aug 2019

An active lifestyle, regardless of vascular risk, may delay the progression of Alzheimer’s disease (AD) by slowing down cognitive decline and neurodegeneration, according to a study presented at the Alzheimer’s Association International Conference (AAIC 2019).

LGBT, gender non-conforming population at greater risk for cognitive decline

Roshini Claire Anthony, 07 Aug 2019

Individuals who identify as sexual or gender minorities (SGM) appear to be at a higher risk of experiencing subjective cognitive decline (SCD) than individuals who identify as cisgender and heterosexual, according to a study presented at the Alzheimer’s Association International Conference (AAIC 2019).

Use of sleep meds may elevate dementia, Alzheimer’s risk

Roshini Claire Anthony, 05 Aug 2019

The use of sleep medications may be associated with the risk of dementia or Alzheimer’s disease (AD) in older adults, according to two studies presented at the recent Alzheimer’s Association International Conference (AAIC 2019).

Multisensory loss may up dementia risk

Audrey Abella, 01 Aug 2019

Multisensory dysfunction is tied to an increased risk of developing dementia or Alzheimer’s disease (AD) in older adults, thus underlining the importance of sensory evaluation in this patient subgroup and among those at risk of developing neurodegenerative illnesses, according to studies presented at AAIC 2019.

Identification of biomarkers one step closer towards blood testing for Alzheimer's

Pearl Toh, 31 Jul 2019

Biomarkers in the blood may present a new opportunity for developing a simple, noninvasive, and inexpensive screening test for Alzheimer’s disease (AD), according to studies presented at the Alzheimer's Association International Conference (AAIC) 2019.

Dementia, Alzheimer’s disease tied to seizure risk

Audrey Abella, 31 Jul 2019

The odds of experiencing seizures and epileptic seizure recurrence were higher among individuals with vs without dementia or Alzheimer’s disease (AD), according to data presented at AAIC 2019.

Men vs women: How the brains are wired differently

Pearl Toh, 26 Jul 2019

Sex-specific differences in the way brain regions are connected may influence how tau propagates through the brain and thus, differences in the risk of Alzheimer’s disease between men and women; while participating in the workforce may help stave cognitive decline in women, suggest studies presented at AAIC 2019.